Alkermes Plc (NASDAQ:ALKS) SVP Iain Michael Brown sold 10,652 shares of the firm’s stock in a transaction dated Friday, December 29th. The stock was sold at an average price of $54.81, for a total value of $583,836.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Iain Michael Brown also recently made the following trade(s):
- On Saturday, December 29th, Iain Michael Brown sold 10,652 shares of Alkermes stock. The stock was sold at an average price of $54.81, for a total value of $583,836.12.
Shares of Alkermes Plc (NASDAQ ALKS) opened at $54.54 on Friday. The stock has a market capitalization of $8,593.77, a P/E ratio of -49.13 and a beta of 2.13. Alkermes Plc has a 12 month low of $46.42 and a 12 month high of $63.40. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05.
ALKS has been the topic of several recent research reports. ValuEngine raised Alkermes from a “sell” rating to a “hold” rating in a research note on Friday, December 1st. Citigroup set a $62.00 price objective on Alkermes and gave the stock a “hold” rating in a research note on Thursday, October 26th. BidaskClub raised Alkermes from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th. Credit Suisse Group decreased their price objective on Alkermes from $70.00 to $66.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. Finally, Barclays set a $50.00 price objective on Alkermes and gave the stock a “hold” rating in a research note on Thursday, October 26th. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $63.55.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC raised its stake in Alkermes by 0.4% during the 2nd quarter. FMR LLC now owns 22,978,575 shares of the company’s stock valued at $1,332,068,000 after purchasing an additional 96,457 shares during the period. Vanguard Group Inc. raised its stake in Alkermes by 3.7% during the 2nd quarter. Vanguard Group Inc. now owns 12,546,198 shares of the company’s stock valued at $727,303,000 after purchasing an additional 449,563 shares during the period. Woodford Investment Management Ltd raised its stake in Alkermes by 2.4% during the 2nd quarter. Woodford Investment Management Ltd now owns 7,647,977 shares of the company’s stock valued at $443,353,000 after purchasing an additional 177,449 shares during the period. Thornburg Investment Management Inc. raised its stake in Alkermes by 39.8% during the 3rd quarter. Thornburg Investment Management Inc. now owns 2,779,364 shares of the company’s stock valued at $141,303,000 after purchasing an additional 790,692 shares during the period. Finally, Janus Henderson Group PLC raised its stake in Alkermes by 13.7% during the 3rd quarter. Janus Henderson Group PLC now owns 2,650,006 shares of the company’s stock valued at $134,726,000 after purchasing an additional 319,014 shares during the period. 99.17% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This article was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3126528/alkermes-plc-alks-svp-sells-583836-12-in-stock.html.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.